The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 31, No. 6, pp. 677-682.
© 1997 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gardner, S.
Right arrow Articles by Fonseca, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gardner, S.
Right arrow Articles by Fonseca, V.

Research Articles

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control

SF Gardner, MA Marx, LM White, MC Granberry, DR Skelton, and VA Fonseca

OBJECTIVE: To determine the efficacy and tolerability of the addition of low-dose niacin (1.5 g/d) in a diabetic hypercholesterolemic population who were unable to attain desired lipid control with low-dose (20 mg) pravastatin monotherapy. RESEARCH DESIGN AND METHODS: This was a prospective, open-label study conducted over a 14-week period. Twenty-three diabetic patients with low-density lipoprotein (LDL) cholesterol concentrations of at least 150 mg/dL after dietary therapy were recruited from the outpatient diabetes clinic of a university teaching hospital. After 4 weeks of dietary stabilization and baseline determination of the lipid profile and glycemic control, patients received pravastatin 20 mg once daily for 4 weeks. Laboratory parameters were reassessed and niacin was added to the regimen in qualifying patients. Over 2 weeks, patients' regimens were titrated to a maximal dosage of 500 mg tid. Patients continued to receive the combination regimen for 4 weeks and were reassessed. MEASUREMENTS AND MAIN RESULTS: Sixteen patients (14 non-insulin-dependent diabetes mellitus, 2 insulin-dependent diabetes mellitus) completed the study. Mean fasting blood sugar and fructosamine concentrations were unchanged throughout the study. Five patients required minor alterations (3 increased, 2 decreased) in their hypoglycemic regimens during the study. The addition of low-dose niacin to pravastatin therapy resulted in a significant lowering of LDL cholesterol compared with pravastatin monotherapy. CONCLUSIONS: Low-dose niacin is a promising addition to hydroxymethylglutaryl-coenzyme A reductase inhibitor therapy in the treatment of hypercholesterolemia in patients with diabetes mellitus.


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
R. B. Goldberg and T. A. Jacobson
Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Mayo Clin. Proc., April 1, 2008; 83(4): 470 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. McKenney
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
Arch Intern Med, April 12, 2004; 164(7): 697 - 705.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. T Yim and P. H Chong
Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Ann. Pharmacother., January 1, 2003; 37(1): 106 - 115.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1997 by Harvey Whitney Books Company.